Search Videos by Topic or Participant
Browse by Series:

Targeted Therapies in Neuroendocrine Tumors

Panelists: Matthew H. Kulke, MD, Dana-Farber; Pamela L. Kunz, MD, Stanford; Rodney F. Pommier, MD, OHSU; James C. Yao, MD, MD Anderson
Published: Wednesday, Apr 17, 2013
For High-Definition, Click
The clinical benefits of targeted therapies in neuroendocrine tumors (NETs) have primarily been restricted to the pancreatic type. However, clinical trials are currently under way examining the mTOR inhibitor everolimus in a broader patient population.

The RADIANT-2 trial examined everolimus plus octreotide compared to octreotide and placebo as a treatment for patients with carcinoid tumors, James C. Yao, MD, explains. The hazard ratio for progression-free survival in this trial was 0.77 in favor of treatment with everolimus; however, this benefit was not statistically significant. To further cull out the benefits of everolimus in this population, the RADIANT-4 trial will examine everolimus plus best supportive care compared to supportive care and placebo.

Overall, the efficacy of targeted agents in NETs varies by location with a clear divide appearing between pancreatic NETs and carcinoids. Furthermore, Yao notes, as research continues, a subclassification within carcinoid types may become more apparent. The further subdivision of NETs will be shaped by ongoing trials, Yao believes.

Two important phase III trials in this space, Yao notes, have finished accrual and will help shape further understanding of subclasses. The CLARINET study, Yao notes, is examining lanreotide versus placebo in non-functioning enteropancraetic NETs. Additionally, the SWOG 0518 study is looking at octreotide with interferon alfa-2b compared to octreotide and bevacizumab for advanced, high-risk, NETs.
Slider Left
Slider Right
For High-Definition, Click
The clinical benefits of targeted therapies in neuroendocrine tumors (NETs) have primarily been restricted to the pancreatic type. However, clinical trials are currently under way examining the mTOR inhibitor everolimus in a broader patient population.

The RADIANT-2 trial examined everolimus plus octreotide compared to octreotide and placebo as a treatment for patients with carcinoid tumors, James C. Yao, MD, explains. The hazard ratio for progression-free survival in this trial was 0.77 in favor of treatment with everolimus; however, this benefit was not statistically significant. To further cull out the benefits of everolimus in this population, the RADIANT-4 trial will examine everolimus plus best supportive care compared to supportive care and placebo.

Overall, the efficacy of targeted agents in NETs varies by location with a clear divide appearing between pancreatic NETs and carcinoids. Furthermore, Yao notes, as research continues, a subclassification within carcinoid types may become more apparent. The further subdivision of NETs will be shaped by ongoing trials, Yao believes.

Two important phase III trials in this space, Yao notes, have finished accrual and will help shape further understanding of subclasses. The CLARINET study, Yao notes, is examining lanreotide versus placebo in non-functioning enteropancraetic NETs. Additionally, the SWOG 0518 study is looking at octreotide with interferon alfa-2b compared to octreotide and bevacizumab for advanced, high-risk, NETs.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x